CAR-Ts are already approved. Rarely, if ever, do you get to run a cancer trial in which the therapy being studied is given priority over already approved therapies. Doctors are going to recommend approved treatments until they don't work and then they'll recommend participation in an experimental trial. Have to remember that just because the PI trial showed promise doesn't mean the results will be the same in a PII. This also makes the path to approval easier. When they chose AML as their first indication, even though lymphoma had the better results, the main reason given was because there was a lot more competition in the lymphoma space and the path to an AML approval would be easier. With the lymphoma trial being specifically for patients who have failed, or are not eligible, for CAR-T the path to approval becomes easier as they are not competing with the CAR-Ts.
To address your other post, CD-19 is expressed in all B cells. This includes the healthy B cells. So when you target CD19 you are not only killing the cancer cells you are also killing healthy cells. Hence the toxicity with CAR-Ts. I would assume this is the reason CD19 is not included as a target in MultiTAA. The antigens Marker is targeting are specifically overexpressed in cancer cells, not healthy cells. This is just my understanding.
News 
Market Data 
Discover 
